Status:
RECRUITING
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use E-cigarettes and Cannabis (Co-Tox Study)
Lead Sponsor:
Roswell Park Cancer Institute
Conditions:
Cigarette Smoking-Related Carcinoma
E-Cig Use
Eligibility:
All Genders
18-25 years
Brief Summary
This study evaluates the amount of nicotine, cannabis, and toxicants linked to the use of nicotine e-cigarette and/or cannabis products in the blood and urine of young adult users as well as the canna...
Detailed Description
PRIMARY OBJECTIVE: I. To evaluate differences in self-reported nicotine and cannabis use behaviors and biomarkers of exposure to toxicants and carcinogens by product use status, to generate effect si...
Eligibility Criteria
Inclusion
- Young adult (18-25 years old).
- Ability to read and write in English.
- Participants must fall into one of the following groups (based on self-report):
- Predominant e-cigarette consumer: defined as using nicotine-containing e-cigarettes daily for the past six months but not having used other nicotine containing products more than weekly or cannabis products for the past month.
- Predominant cannabis consumer: defined as using cannabis at least 3x/week for the past six months in any form, including smoking, vaping, and oral use, with no more than weekly use of any nicotine or tobacco products.
- E-cigarette-cannabis co-consumers: defined as daily use of nicotine e-cigarettes and use of cannabis at least 3x/week, including smoking, vaping, and oral use, for at least the past six months, with no use of other nicotine containing products more than weekly.
- No self-reported diagnosis of kidney disease (current, or within the past year prior to the study visit).
- Participants must understand the voluntary nature of this study and sign a written informed consent form before proceeding with study activities.
Exclusion
- Individuals under the age of 18 or over the age of 25.
- Currently pregnant or breastfeeding (female participants).
- Unwilling or unable to follow protocol requirements
Key Trial Info
Start Date :
April 3 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2028
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07167225
Start Date
April 3 2025
End Date
September 1 2028
Last Update
October 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States, 14263